Effectiveness of WearME System for FEV1/FVC, Respiration and Activity Biomarkers in COPD Patients
LASARRUS Clinic and Research Center
Summary
This observational study evaluates the effectiveness of the WearME system in monitoring COPD severity and respiratory function by comparing its measurements to standard spirometry, capnography, and other clinical assessments in 128 COPD participants.
Description
COPD is the third leading cause of death worldwide, with over 3 million deaths and an estimated total cost of $52 billion in the U.S. alone. This project, in collaboration with the Johns Hopkins Clinical Research Network (JHCRN), aims to provide technological innovation access to underserved patients in low-income, rural, and diverse ethnicities in the Mid-Atlantic region. The symptoms of COPD include dyspnea (shortness of breath), coughing and the production of sputum. Recent data shows that the 30-day readmission rate of COPD patients is approaching 23%, creating a huge burden on the health…
Eligibility
- Age range
- 21–100 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Adult participants aged 21-100 years, of any sex, and of any race/ethnicity, who are able to understand and sign consent documents in English or Spanish. * Diagnosed with COPD as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria \[5\] , with the following severity levels (confirmed via spirometry performed after consent): * Mild: FEV1/FVC \< 0.7 and FEV1 ≥ 80% * Moderate: FEV1/FVC \< 0.7 and 50% ≤ FEV1 \< 80% * Severe: FEV1/FVC \< 0.7 and 30% ≤ FEV1 \< 50% * Very Severe: FEV1/FVC \< 0.7 and FEV1 \< 30% or FEV1 \< 50%, plus chronic re…
Locations (2)
- Johns HopkinsBaltimore, Maryland
- TidalHealthSalisbury, Maryland